NeOnc Technologies Reports Third Quarter 2026 Financial Results
NeOnc Technologies Holdings, Inc. announced its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical development programs.
Stocks · News reference
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
NeOnc Technologies Holdings, Inc. announced its financial results for the third quarter ended September 30, 2026, alongside updates on its clinical development programs.
Eton Pharmaceuticals released preliminary results from a pilot study of ET-700, an investigational extended-release zinc acetate formulation for Wilson disease, showing improved tolerability compared to GALZIN.
Eton Pharmaceuticals exceeded expectations in Q3 2026 with revenues of $57.9M (158% YoY growth) and raised full-year revenue guidance to over $175M with adjusted EBITDA margins above 40%. The company achieved its $200M annualized revenue run-rate target five quarters ahead of schedule, driven primarily by HEMANGEOL sales. Eton is preparing for an April 2027 LIBERVANT launch and advancing its pipeline including ASN-001 and ET-900.
Eton Pharmaceuticals announced that its executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London in November 2026.
Eton Pharmaceuticals reported record third-quarter 2026 revenue of $57.9 million, a 158% year-over-year increase, and raised its full-year 2026 financial guidance.
Filed: 2026-11-05 AccNo: 0001829126-26-012024 Size: 239 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits